Breast, Europe, SABCS 2008

Flash player required  Flash player required

You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.

Dr John Bartlett - Professor of Molecular Pathology, Edinburgh University

New biomarker predicts anthracycline response

The presence of chromosome 17 polysomy effectively predicted which patients would benefit from adjuvant anthracycline chemotherapy. Researchers analyzed 1,625 samples from NEAT (National Epirubicin Adjuvant Trial) and found that those patients with C17 polysomic tumours had significantly greater benefit from epirubicin than those without, even when taking HER2 status into consideration. Researchers suggest that this may explain the apparent association of anthracycline sensitivity and HER2 status which is located on this chromosome. Speaking at the 2008 San Antonio Breast Cancer Symposium.

Views: 4872   Added: 11/03/2009    Comments: 0

00:07:15

77 Ratings 
  • Currently 2/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
Bookmark and Share

Comments on this video Report unsuitable comment

No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.

Add a comment